Charles Schwab Investment Management Inc. Boosts Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Charles Schwab Investment Management Inc. increased its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 3.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 166,054 shares of the biotechnology company’s stock after buying an additional 5,733 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in AnaptysBio were worth $2,199,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its position in shares of AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 644 shares during the period. Point72 DIFC Ltd increased its holdings in AnaptysBio by 680.5% in the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 5,342 shares in the last quarter. SG Americas Securities LLC raised its position in AnaptysBio by 35.0% during the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 4,231 shares during the period. Intech Investment Management LLC purchased a new position in AnaptysBio during the third quarter valued at $229,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of AnaptysBio in the third quarter valued at about $250,000.

Insider Activity at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock in a transaction dated Thursday, January 2nd. The stock was bought at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the purchase, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 33.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ANAB shares. Wolfe Research assumed coverage on AnaptysBio in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 target price on the stock. Wells Fargo & Company increased their price target on shares of AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Wedbush restated an “outperform” rating and issued a $40.00 price objective on shares of AnaptysBio in a report on Wednesday, February 12th. HC Wainwright restated a “neutral” rating and set a $22.00 price target on shares of AnaptysBio in a research note on Tuesday, March 4th. Finally, Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research note on Monday, March 3rd. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.11.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $18.95 on Friday. The business has a 50-day moving average of $17.14 and a two-hundred day moving average of $22.05. The company has a market capitalization of $581.14 million, a price-to-earnings ratio of -3.12 and a beta of 0.02. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.61) by $0.89. The company had revenue of $43.11 million during the quarter, compared to the consensus estimate of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, equities research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its board has authorized a share buyback plan on Monday, March 24th that allows the company to repurchase $75.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to repurchase up to 13.1% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.